Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma

Clinical Cancer Research

Volumn 15, Issue 18, 2009, Pages 5820-5828

  Ou, Da Liang ^a   Shen, Ying Chun ^a,b   Liang, Ja Der ^a   Liou, Jun Yang ^c   Yu, Sung Liang ^b   Fan, Hsiang Hsuan ^a   Wang, Da Sheng ^d   Lu, Yen Shen ^a   Hsu, Chiun ^a   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SMALL INTERFERING RNA; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZAMIDES; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PYRIDINES; RAF KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 70349452270     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3294     Document Type: Article

References (39)

1. Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncol 2007;2:199-210.
2. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109 (Pubitemid 39331023)
3. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
5. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-11858 (Pubitemid 46094197)
6. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-3310
7. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14:342-346
8. LoRusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK Inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-5293 (Pubitemid 46206982)
9. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008;22:808-818 (Pubitemid 351552630)
10. Yu C, Bruzek LM, Meng XW, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY43-9006. Oncogene 2005;24:6861-6869 (Pubitemid 41509409)
11. Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl + human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 downregulation. Mol Pharmacol 2007;72:788-795 (Pubitemid 47351213)
12. Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 2005;12:1008-1014 (Pubitemid 41065418)
13. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein Bim. J Biol Chem 2003;278:18811-18816 (Pubitemid 36799262)
14. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
15. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the proapoptotic bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-1. Curr Biol 2000;10:1201-1204 (Pubitemid 30816681)
16. Hu MC, Lee DF, Xia W, et al. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004;117:225-237 (Pubitemid 38496242)
17. O'Shaughnessy J, Blackwell KL, Burstein H, et al. Aran domized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008;26:abstr 1015.
18. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-1639 (Pubitemid 43259947)
19. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the ras-mitogen-activated protein kinase pathway. Clin Cancer Res 2008;14:3651-3656
20. Dummer R, Robert C, Chapman PB, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. J Clin Oncol 2008;26:abstr 9033.
21. Solit DB, Santos E, Pratilas CA, et al. 3′-Deoxy-3′-[18F] fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007;67:11463-11469 (Pubitemid 350248575)
22. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-2146
23. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-362
24. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403. (Pubitemid 40193310)
25. Puthalakath H, O'Reilly LA, Gunn P, et al. ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 2007;129:1337-1349 (Pubitemid 46962086)
26. Reginato MJ, Mills KR, Paulus JK, et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003;5:733-740
27. Schulze-Bergkamen H, Fleischer B, Schuchmann M, et al. Suppression of Mcl-I via RNA interference sensitizes human hepatocellular carcinoma cells toward apoptosis induction. BMC Cancer 2006;6:232-245 (Pubitemid 44575143)
28. Kim SH, Ricci S, El-Deiry WS. Mcl-1: a gateway to trail sensitization. Cancer Res 2008;68:2062-2064
29. Ding Q, Huo L, Yang JY, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res 2008;68:6109-6117
30. Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007;67:9490-9500 (Pubitemid 47535939)
31. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006;66:1611-1619 (Pubitemid 43259945)
32. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008;7:496-501.
33. Sosman JA, Flaherty KT, Atkins MB, et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008;26:abstr 5011.
34. Shen YC, Shao YY, Hsu C, et al. Phase II study of sorafenib plus tegafur/uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2008;26:abstr 15664.
35. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006;66:3351-3354
36. Tashiro T, Inaba M, Kobayashi T, et al. Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol 1989;24:187-192 (Pubitemid 19163404)
37. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans. Cancer Biol Ther 2003;2(suppl 1):S134-9.
38. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004;40:837-844 (Pubitemid 38519762)
39. Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007;67:4933-4939 (Pubitemid 46910201)